Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)

Ramón García‐Sánz, Anna Sureda, Fátima De la Cruz, Miguel Canales, Ana Pilar González, José Luís Piñana, Á. Rodríguez, Antonio Gutiérrez, Eva Domingo‐Doménech, Blanca Sánchez‐González,

Annals of Oncology · 2019 · 124 citations · 32 references

DOIFull text

Open access

Concepts

References

32